Coenzyme Q10 (CoQ10)

LCD Information Document Information Source LCD ID N/A LCD ID L37126 Original ICD-9 LCD ID Not Applicable LCD Title Coenzyme Q10 (CoQ10) Proposed LCD in Comment Period N/A Source Proposed LCD DL37126 Opens in a new window Original Effective Date For services performed on or after 07/10/2017 Revision Effective Date For services performed on or after 01/22/2026 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 05/25/2017 Notice Period End Date 07/09/2017 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity. Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis and treatment of illness or injury or to improve the functioning of a malformed body member. 42 CFR §410.32(a) indicates that diagnostic tests may be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements). Coverage Indications, Limitations, and/or Medical Necessity This is a non-coverage policy for serum or other body fluid testing for levels of Coenzyme Q10 (CoQ10 or Q10), also known as ubiquinone, ubidecarenone, coenzyme Q, for all diseases. Q10 supplementation is purported to: Prolong life and prevent age-related functional declines Inhibit the development and/or progression of atherosclerosis Have value as an adjunct to conventional medical therapy in the treatment of congestive heart failure, conventional angina therapy, and cancer Is protective against myocardial damage during ischemia-reperfusion during cardiac surgery Is beneficial in the treatment of hypertension, cardiovascular disease and diabetes Plays a role in neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia Enhance athletic performance Enhance fertility However, scientific indications for Q10 supplementation, except as anecdotally reported for rare mitochondrial encephalomyopathies, are poor and/or controversial, as are indications for Q10 testing by any methodology.Q10 is a highly lipophilic molecule with a chemical structure similar to vitamin K. Its most prominent role is to facilitate the production of adenosine triphosphate (ATP) in the mitochondria by participating in redox reactions within the electron transport chain. Two major factors lead to deficiency of Q10 in humans: reduced biosynthesis and increased use by the body. As many as 12 genes control biosynthesis; Q10 levels may also be controlled by other genetic defects not directly related to Q10 biosynthesis. Summary of Evidence Heart disease Q10 shares a biosynthetic pathway with cholesterol. An intermediary precursor of Q10 is inhibited by some beta blockers, antihypertensive medications and statins, but the role of statins in deficiencies is controversial.1Some chronic disease conditions (cancer, heart disease, etc.) are also thought to reduce the biosynthesis of and increase the demand for CoQ10 in the body, but there is no definite data to support these claims.2 A 2014 Cochrane Collaboration meta-analysis found "no convincing evidence to support or refute" the use of CoQ10 for the treatment of heart failure.3 Evidence with respect to preventing heart disease in those who are otherwise healthy is also poor.4Statin myopathy Q10 has been routinely used to treat muscle breakdown associated as a side effect of use of statin medications. However, evidence from randomized controlled trials does not appear to support the idea that CoQ10 is an effective treatment for statin myopathy.5Cancer No large well-designed clinical trials of CoQ10 in cancer treatment have been done.6 The National Cancer Institute identified issues with the few, small studies that have been done stating, "the way the studies were done and the amount of information reported made it unclear if benefits were caused by the CoQ10 or by something else".6 The American Cancer Society has concluded, "CoQ10 may reduce the effectiveness of chemo and radiation therapy, so most oncologists would recommend avoiding it during cancer treatment."Neuromuscular and Neurologic Diseases Available evidence suggests that "CoQ10 is likely ineffective in moderately improving" the chorea associated with Huntington's disease.7Migraine headache Supplementation of CoQ10 has been found to have a beneficial effect on the condition of some sufferers of migraine. An explanation for this is the theory that migraines are a mitochondrial disorder,8 and that mitochondrial dysfunction can be improved with CoQ10.9 The Canadian Headache Society guideline for migraine prophylaxis recommends, based on low-quality evidence, that 300 mg of CoQ10 be offered as a choice for prophylaxis.10Dental disease A review study has shown that there is no clinical benefit to the use of CoQ10 in the treatment of periodontal disease.11 Most of the studies suggesting otherwise were outdated, focused on in vitro tests, too few test subjects and/or erroneous statistical methodology and trial setup, or were sponsored by a manufacturer of the product.Mitochondrial encephalomyopathies This group of genetic disorders results from abnormalities in the function of the mitochondrial transport chain. Tissue Q10 deficiencies have been found in a very small subpopulation of individuals with mitochondrial encephalomyopathies.12 In these rare individuals, Q10 supplementation has resulted in clinical improvement.13Male infertilityQ10 can improve some measurements regarding sperm quality. However, there is no evidence that Q10 increases pregnancy rates or live births.14 Analysis of Evidence (Rationale for Determination) Level of Evidence Quality – 2C Strength – Weak Weight – Weak Based on the results of multiple articles representing multiple conditions, the scientific evidence to support coverage of Q10 for any purpose is controversial and/or limited for all diseases. Thus, testing for Coenzyme Q10 is not reasonable and necessary as a Medicare benefit. Randomized controlled studies are recommended to demonstrate clinical utility. Consequently, testing for Q10 is not a Medicare benefit.

This is a non-coverage policy for serum or other body fluid testing for levels of Coenzyme Q10 (CoQ10 or Q10), also known as ubiquinone, ubidecarenone, coenzyme Q, for all diseases. Q10 supplementation is purported to: Prolong life and prevent age-related functional declines Inhibit the development and/or progression of atherosclerosis Have value as an adjunct to conventional medical therapy in the treatment of congestive heart failure, conventional angina therapy, and cancer Is protective against myocardial damage during ischemia-reperfusion during cardiac surgery Is beneficial in the treatment of hypertension, cardiovascular disease and diabetes Plays a role in neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia Enhance athletic performance Enhance fertility However, scientific indications for Q10 supplementation, except as anecdotally reported for rare mitochondrial encephalomyopathies, are poor and/or controversial, as are indications for Q10 testing by any methodology. Q10 is a highly lipophilic molecule with a chemical structure similar to vitamin K. Its most prominent role is to facilitate the production of adenosine triphosphate (ATP) in the mitochondria by participating in redox reactions within the electron transport chain. Two major factors lead to deficiency of Q10 in humans: reduced biosynthesis and increased use by the body. As many as 12 genes control biosynthesis; Q10 levels may also be controlled by other genetic defects not directly related to Q10 biosynthesis.